ANZCTR search results

This pilot randomised controlled trial will compare the feasibility of delivering the pre-clinic STEPS pain education program online versus face-to-face for patients on the chronic pain waitlist at Royal Prince Alfred Hospital and Westmead Hospital Pain Clinics. Participants will be randomised to receive either virtual or in-person STEPS sessions prior to their first multidisciplinary pain clinic appointment. Feasibility outcomes will include recruitment and retention rates, program completion, and acceptability to participants and staff. Secondary outcomes will assess preliminary clinical effectiveness, equity of access, health service impact, and participant experiences. Findings will inform the scalability and implementation of flexible STEPS delivery models across pain services.

Improvements to transplant outcomes are made possible through access to high quality clinical information and biological samples. Clinical information can be used to identify areas to improve patient care, inform clinical guidelines and to provide insights into problems about how to diagnose and treat diseases. The TRIBE aims to improve transplant outcomes by developing a transplant-related registry of clinical information linked with biological samples (e.g. blood, urine) which can be used to inform quality improvement activities and to support transplant-related research.

he investigators are investigating whether pelvic floor physiotherapy can reduce the risk of repeated episodes of diverticulitis. As far as the investigators are aware, this would be the first prospective study to explore this relationship. An understanding of the nonoperative options available to patients with diverticulosis is necessary for limiting further readmissions, operations and morbidity related to diverticular disease.

Tranexamic Acid (TXA) is a commonly used medication which has been shown in many studies to reduce blood loss after total joint replacement. TXA is approved for use in Australia by the Australian Federal Government. TXA administration is widely endorsed as best practice after total joint replacement by the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anaesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. We are conducting a study to validate whether extended oral TXA use post surgery can improve total hip and knee replacement outcomes to improve confidence in its routine administration (during surgery) after total joint replacement.

This pilot randomised controlled clinical trial will explore the feasibility of delivering a new, telehealth intervention to individuals with a stimulant use disorder and traumatic brain injury. It aims to generate exploratory data on treatment engagement, change in stimulant use, community participation, and healthcare utilisation/costs that could inform hypotheses for a larger clinical trial.

Diabetic patients are at higher risk of stent failure and heart attacks following percutaneous coronary intervention (PCI). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are second-line therapy in diabetes and certain SGLT2i (empagliflozin) have been shown to reduce cardiovascular events. Observational data have suggested reduced coronary restenosis rates with SGLT2i following PCI, regardless of glycaemic control. An animal model study demonstrated the plaque-stabilising effects of SGLT2i through the reduction in lipid core and increasing fibrous cap thickness. This study explores the role of empagliflozin in reducing the risk of coronary stent restenosis in diabetic patients. Diabetic patients undergoing PCI in a non-emergency setting will be randomised to either empagliflozin or standard of care (non-SGLT2 inhibitor treatments for diabetes). All patients will receive intravascular imaging at baseline and at 9 months following PCI. The primary outcome of this study is the degree of lumen loss at follow-up, a marker of stent restenosis. Other markers that will be examined include strut coverage, stent mal-apposition and neo-intimal growth. In the world’s first study, we will also examine the impact of empagliflozin on coronary plaque morphology such as fibrous cap thickness, lipid plaque volume and plaque regression over time. This will provide additional knowledge on the impact of SGLT2i on vascular healing and plaque stabilisation.

This randomised controlled trial aims to determine the effect of Expiratory Muscle Strength Training (EMST) on treating dysphagia in critical illness. Early research has suggested that strengthening the swallowing and respiratory musculature, through a type of treatment called “Expiratory Muscle Strength Training (EMST)”, might be helpful in improving swallowing function to assist the transition back to eating and drinking after a period of not having any food or drink by mouth. However, what is currently not known is that if this is any better than our “usual care”.

This study aims to determine whether infusing platelet-rich plasma (PRP) into the cavity of the womb can improve the chances of pregnancy for women who have experienced repeated unsuccessful in vitro fertilisation (IVF) attempts. PRP is derived from a small sample of the woman’s own blood and contains concentrated natural substances (growth factors) that promote healing and tissue regeneration. PRP has been successfully applied in other areas of medicine to support healing. This study will explore whether it can help prepare the uterus for a successful pregnancy. Participants will include women undergoing IVF who have experienced repeated unsuccessful implantation despite using high-quality embryos. They will be randomly assigned to one of two groups: one will receive PRP, and the other will have a similar procedure without PRP. For those in the PRP group, a small blood sample will be taken and processed to produce PRP, and the PRP will be gently infused into the uterus, two days before the embryo transfer. The study will span approximately five years to enable monitoring of pregnancy outcomes, including implantation, clinical pregnancy, miscarriage, and live birth rates. The research team is committed to ensuring participant safety, with all procedures performed by trained professionals. This study explores a potential new treatment option for women who have experienced repeated IVF failures.

What is the purpose of this clinical trial? The main goal of this study is to assess how well a new imaging agent, called 68Ga-3BP-6146, can detect solid tumour lesions in people with advanced cancer. Who is it for? You may be eligible to take part in this study if you are an adult who has been diagnosed with non-small-cell lung cancer, breast cancer, or gastrointestinal cancer (excluding neuroendocrine tumours). What does the study involve? All participants will receive a single injection of the imaging agent 68Ga-3BP-6146, which binds to a protein called uPAR that may be present on some cancer cells. Participants will then undergo PET/CT scans at 1 hour and 4 hours after the injection. Each scan will take approximately 16 minutes. You will also be monitored for any possible side effects during the imaging process and for 48 hours after the injection. [If applicable: Additional blood tests or safety assessments may be performed during this time.] What is the potential benefit? It is hoped that this study will help determine whether this new imaging agent can effectively detect tumours, which may assist in future research and clinical care.

This pilot study will investigate whether consuming purple and red-rich fruits can improve inflammation, oxidative stress, adiponectin levels, and memory in adults living with obesity. Over six weeks, participants will be randomly assigned to consume red dragon fruit juice (rich in betalains), Queen Garnet plum extract (rich in anthocyanins), or a placebo drink. Blood samples will be analysed for markers of inflammation (e.g. TNF-a, IL-6), oxidative stress, and adiponectin. Cognitive function, mood, and clinical health indicators will also be assessed. The results may help clarify the potential benefits of natural fruit compounds for metabolic and brain health.